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ABSTRACT
Background: Declining platelet counts may reveal platelet activation and aggregation 
in a postoperative prothrombotic state. Therefore, we hypothesized that nadir platelet 
counts after on-pump coronary artery bypass grafting (CABG) surgery are associated 
with stroke.
Methods: We evaluated 6,130 adult CABG surgery patients. Postoperative platelet 
counts were evaluated as continuous and categorical (mild vs. moderate to severe) 
predictors of stroke. Extended Cox proportional hazard regression analysis with a time-
varying covariate for daily minimum postoperative platelet count assessed the 
association of day-to-day variations in postoperative platelet count with time to stroke. 
Competing risks proportional hazard regression models examined associations between 
day-to-day variations in postoperative platelet counts with timing of stroke (early: 0-1 
days; delayed: ≥2 days). 
Results: Median [interquartile range] postoperative nadir platelet counts were 123.0
[98.0, 155.0] x 10
9
/L. The incidences of postoperative stroke were 1.09%, 1.50%, and 
3.02% for platelet counts, >150x10
9
/L, 100-150x10
9
/L, and <100x10
9
/L, respectively. 
The risk for stroke increased by 12% on a given postoperative day for every 30 x 10
9
/L 
decrease in platelet counts (adjusted hazard ratio [HR], 1.12; 95% confidence interval 
[CI], 1.01-1.24; P=0.0255). On a given day, patients with moderate to severe 
thrombocytopenia were twice as likely to develop stroke (adjusted HR, 1.99; 95% CI, 
1.18-3.34; P=0.0093) as patients with nadir platelet counts >150x10
9
/L. Importantly, 
such thrombocytopenia, defined as a time-varying covariate, was significantly 
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associated with delayed (≥2days after surgery; adjusted HR, 2.87; 95% CI, 1.49-5.55; 
P=0.0016), but not early postoperative stroke. 
Conclusion: Our findings suggest an independent association between moderate to 
severe postoperative thrombocytopenia and postoperative stroke, and timing of stroke 
after CABG surgery.
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INTRODUCTION
Postoperative stroke remains a relatively common and often debilitating 
complication after cardiac surgery, affecting approximately 2% of patients, and carrying 
a 5-fold higher risk for postoperative mortality.(1) Despite important advances in patient 
care, surgical strategies, and cardiopulmonary bypass (CPB) equipment, this incidence 
of stroke has not changed significantly over the past 2 decades.(2) Thus, as increasing 
numbers of older patients with more comorbidities are undergoing cardiac surgery, and 
as more patients are surviving surgery, the prediction, management, and prevention of 
stroke after CABG surgery are healthcare priorities of increasing concern. 
The etiology of stroke after on-pump CABG surgery is complex and 
multifactorial,(3,4) with important differences between early (0-1 days) and delayed (≥ 2 
days) strokes. Most early strokes purportedly arise from particulate and gaseous 
embolism during surgery,(5) and/or are precipitated by intraoperative hemodynamic 
perturbations.(6) In contrast, a crucial factor in the development of delayed strokes is 
likely the prothrombotic postoperative state(7) promoted by significant and protracted 
humoral and cellular inflammatory responses,(8) and platelet activation(9,10) during and 
after cardiac surgery. 
The role of platelets has come under significant scrutiny in various disease 
processes as they are increasingly recognized as important and ubiquitously present 
regulators of tissue inflammation.(11) We recently reported that, similar to observations 
in critically ill patients(12), postoperative thrombocytopenia, defined as the lowest in-
hospital values, is associated with acute kidney injury (AKI) and increased risk for 
mortality after CABG surgery.(13) The cause of the postoperative decline in platelet 
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counts and importantly, the connection between thrombocytopenia and the 
development of adverse outcomes, remain unknown. Because platelet counts 
frequently drop to a nadir after cardiac surgery,(13) the observed thrombocytopenia is 
likely the result of platelet activation and consumption in a setting of systemic 
hypercoagulability. We therefore hypothesized that thrombocytopenia after on-pump 
CABG surgery is associated with postoperative stroke.
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METHODS
Study Population
After approval by the Institutional Review Board for Clinical Investigations at 
Duke University Medical Center (Durham, NC, USA), we conducted this retrospective 
observational study on patients over 18 years old who underwent isolated urgent or 
elective CABG surgery with CPB at the Duke University Medical Center from January 1, 
2001 through July 18, 2015. For patients who had more than one cardiac surgery during 
that period, only data from the first surgery were evaluated. Of the original 6,921 
patients, 6,131 had complete data for preoperative and postoperative platelet counts, 
and met criteria for inclusion in the present study. Of the 6,131 patients analyzed and 
reported in this study, 4,217 have been analyzed as part of a separate publication.(13)
Data Collection
A standard set of perioperative data were collected from Duke University Medical 
Center databases including the Duke Perioperative Electronic Database (Innovian® 
Anesthesia; Draeger Medical Inc, USA), Cardiac Surgery Quality Assurance Database, 
Duke Databank for Cardiovascular Diseases, and from Duke MAESTRO CARE 
(Medical Application Environments Supporting Transformation of Research and 
Operations: http://www.dukehealth.org/maestrocare), Duke Medicine’s platform-based 
electronic health record (Copyright 2016 by Epic Systems Corporation, Verona, WI, 
USA; http://www.epic.com).
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Clinical Risk Factors
The clinical risk factors for postoperative stroke included patient characteristics, 
preoperative and intraoperative cardiovascular medication use including prothrombin 
complex and recombinant factor VII, components of the European System for Cardiac 
Operative Risk Evaluation score (EuroSCORE),(14) CPB and aortic cross-clamp times, 
insertion of intraaortic balloon pump (IABP), intraoperative and postoperative blood 
transfusions, and hemoglobin and platelet counts. According to institutional practice, 
preoperative antiplatelet therapy with aspirin was maintained until the day before 
surgery; clopidogrel was discontinued 7 days or longer before surgery; and warfarin was 
discontinued 4 days before surgery and “bridged” with IV heparin infusion.(13)
Per institutional protocol, platelet counts were also measured preoperatively in 
the Duke Clinical Pathology Laboratory and for the first 10 days postoperatively or until 
discharge, whichever came first, as described previously.(13) We analyzed both the 
association of daily minimum postoperative platelet values, and that of lowest minimum 
(nadir) platelet counts with our stroke outcome. For the analysis of association of nadir 
platelet values we conditionally defined nadir platelets relative to stroke outcomes. 
When stroke preceded the postoperative nadir platelet counts, we used lowest pre-
stroke platelets value as a predictor of postoperative stroke. These values were 
subsequently used as a continuous predictor of postoperative stroke. Further, based on 
laboratory definitions of thrombocytopenia, postoperative platelet values were used as a 
categorical predictor (mild thrombocytopenia [100-150 x 10
9
/L], and moderate to severe 
thrombocytopenia [<100 x 10
9
/L]) and as a threshold for clinical characterization of 
patients with different grades of postoperative thrombocytopenia.
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Similarly, serum hemoglobin concentrations were measured per institutional 
protocol, preoperatively and for the first 10 days postoperatively or until discharge, 
whichever came first. Daily and minimum serum hemoglobin concentrations were 
defined as the lowest in-hospital values measured during the first 10 postoperative days 
or to day of hospital discharge and were considered as adjustment variables in our 
analyses of postoperative stroke.
Classification of Outcome
Postoperative stroke was chosen as the outcome, and was ascertained and 
categorized in a manner similar to the study by Hogue et al.(4) In brief, postoperative 
stroke was defined as any new permanent global or focal neurologic deficit that could 
not be attributed to preexisting neurologic and/or non-neurologic pathophysiologic 
abnormalities. Reversible cerebral ischemic events, such as a transient ischemic attack, 
were not included in the current study because the residual effect of perioperative 
medications could hinder their detection. Per Duke institutional protocol, all patients 
undergoing cardiac surgery were screened daily during the postoperative period to 
identify patients with postoperative stroke. When a new postoperative neurologic deficit 
was detected, a stroke code was initiated. A subsequent diagnosis of stroke was 
established by the attending neurologist, and was substantiated in most patients by 
neuroimaging, eg, CT or MRI head scan. In the current study, the patients’ electronic 
health records were screened for International Classification of Disease-9
th
Revision 
(ICD-9; http://www.cdc.gov/nchs/icd/icd9cm.htm) codes for cerebrovascular accident, 
eg, ischemic (434.91), embolic (434.11), hemorrhagic (430, 431, 432.0-432.9), 
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thrombotic (434.01), and postoperative cerebrovascular accident (997.02). In parallel, 
electronic imaging records, as part of the electronic health records of all patients, were 
screened for the CPT billing codes for a CT scan of the head (70450 [CT scan of the 
head without contrast], 70460 [CT scan of the head with contrast], and 70470 [CT scan 
without contrast followed by a CT procedure with contrast]), and for an MRI scan of the 
brain (70551 [MRI Brain without contrast], 70552 [MRI Brain with contrast], and 70553 
[MRI Brain without contrast followed by an MRI procedure with contrast]). CT and MRI 
scans with a date stamp within 30 days of CABG surgery, were selected and reviewed 
for a diagnosis of acute postoperative stroke. All stroke diagnoses and imaging reports 
were then reviewed by 3 investigators (AEM, JAK, MDK), and the diagnoses and timing 
of strokes were ascertained in relation to the date of surgery. New neurologic deficits 
identified before the end of postoperative day (POD) 1 were classified as early strokes, 
and neurologic deficits that occurred between POD 2 and 30 inclusively, were classified 
as delayed strokes.
STATISTICS
Summary statistics are presented as median (interquartile range) for continuous 
variables, or as group frequencies and percentages for categorical variables by 
categories of postoperative thrombocytopenia that were defined using the lowest in-
hospital value or the lowest platelet value prior to stroke. Kruskal-Wallis or chi-square 
tests were used for descriptive group comparisons as appropriate.
Univariable and multivariable Cox proportional hazard regression models were 
applied to evaluate the unadjusted and adjusted prognostic importance of postoperative 
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platelet counts and risk for postoperative stroke. Given the day-to-day variations in 
postoperative platelet counts and serum hemoglobin concentrations in our study we 
used extended Cox regression analysis with time-varying covariates and hazard ratios 
to model the effects of day-to-day variations in postoperative platelet counts and serum 
hemoglobin concentrations on the risk for postoperative stroke.(15-17) We defined the 
time-varying platelet counts variable (both categorical and continuous) in our 
proportional hazards models based on the most recent daily minimum platelet counts
relative to the time being evaluated.  For all time points after discharge or POD 10, 
whichever came first, time-varying platelet counts model term were based on the last 
recorded daily minimum value. The resulting hazard ratio estimates for effect of 
postoperative platelet counts in these models should be interpreted as comparisons of 
the hazard for two patients with different postoperative platelet counts on the same day 
after surgery. Univariable associations with P < 0.10 were evaluated using a forward 
stepwise technique to derive the final multivariable Cox proportional hazard regression 
model containing variables with P < 0.05. Continuous variables (ie, age, serum 
creatinine, hemoglobin and platelet counts, and duration of CPB time) were evaluated 
for nonlinearity, and transformations were performed if warranted. Of note, including 
time-dependent covariates for postoperative platelet counts and serum hemoglobin 
concentrations precluded us from the evaluation of the discriminatory ability and 
calibration of the final multivariable Cox regression models.
In a subsequent analysis, we investigated the association between daily 
postoperative platelet counts and timing of stroke using the Fine-Gray method of 
proportional hazard models for the subdistribution of early and delayed strokes.(18)
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Under the Fine-Gray method, the subdistribution hazard for a given subevent is defined 
as the hazard for a patient who either suffers the subevent or not, and expands the risk 
set at a given time to include both those who have experienced a different subevent and 
those who are currently event free. This analysis method allows us to estimate the 
effect of daily postoperative platelet counts on the absolute risk of early and delayed 
stroke, and to estimate the cumulative impact of daily postoperative platelet counts on 
patient stroke prognosis.(19) We built multivariable models separately for each 
subevent using forward stepwise technique to derive final multivariable proportional 
hazards models containing variables with P < 0.05 for early and delayed stroke events. 
As in the main analysis, we used a time-varying effect for day-to-day variations in 
postoperative platelet counts (both categorical and continuous).
A sensitivity analysis was also performed to determine whether exclusion of 
patients with heparin-induced thrombocytopenia (HIT) affected the observed association 
between thrombocytopenia and stroke. The presence of HIT was ascertained by 
reviewing the patients’ electronic health records for the diagnosis of HIT, and by 
searching laboratory records for enzyme-linked immunosorbent assays that were 
positive for human platelet factor 4/heparin complex antibodies. Hazard ratios (HRs) 
and odds ratios (ORs) with corresponding 95% confidence limits are reported. SAS 
Version 9.4 (SAS Institute Inc, USA) was used for all statistical analyses.
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RESULTS
The overall median [interquartile range] for postoperative nadir platelet counts 
was 123.0 [98.0, 155.0] x 10
9
/L. The 6,130 patients studied were separated into 3 
groups according to postoperative nadir platelet counts: (1) no thrombocytopenia (>150 
x 10
9
/L; 27%, n = 1,750); (2) mild thrombocytopenia (100-150 x 10
9
/L; 44.4%, n = 
2,726); and (3) moderate to severe thrombocytopenia (<100 x 10
9
/L; 28.6%, n = 1,654).
Demographic and clinical characteristics of the 3 groups according to postoperative 
nadir platelet counts are compared in Table 1. Several significant differences between 
the groups were found including age, race, female sex, medical history, comorbidities, 
preoperative and intraoperative medication use, and intraoperative characteristics. Of 
note, none of the patients who developed stroke had received prothrombin complex or 
recombinant factor VII. 
Postoperative Stroke
The overall incidence of postoperative stroke was 1.8% (n = 110) within 30 days 
after surgery. In 101 patients (91%), the diagnosis of postoperative stroke was 
substantiated by neuroimaging such as a CT or MRI head scan; and in 9 patients (9%), 
the stroke diagnosis was established by the attending neurologist. Most of these strokes 
were ischemic (90%). Of the remainder, 4.5% were hemorrhagic, and 5.5% were 
embolic strokes. In cohorts with no thrombocytopenia, mild thrombocytopenia, and 
moderate to severe thrombocytopenia, the incidence of stroke was 1.09% (n = 19), 
1.50% (n = 41), and 3.02% (n = 50), respectively.
Univariable predictors of postoperative stroke are shown in Table 2. Several 
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preoperative and intraoperative variables were significantly associated with an 
increased risk for postoperative stroke (Table 2). Daily postoperative platelet counts as 
a time-varying covariate, defined as mild thrombocytopenia 100 - 150 x 10
9
/L 
(unadjusted HR, 1.64; 95% CI, 1.02-2.62; P = 0.0406), moderate to severe 
thrombocytopenia <100 x 10
9
/L (unadjusted HR, 2.77; 95% CI, 1.66-4.61; P < 0.0001),
or as a continuous variable for every 30 × 10
9
/L daily decrease (univariable HR, 1.19; 
95% CI, 1.07-1.32; P = 0.001), were significantly associated with postoperative stroke. 
According to our multivariable analysis, age, history of peripheral vascular disease 
(PVD), intraoperative insertion of IABP, and packed red blood cell transfusion were 
independent risk factors for postoperative stroke, whereas preoperative statin use was 
associated with a reduced risk for postoperative stroke (Table 2). After adjusting for 
differences in baseline and clinical characteristics, categorical postoperative 
thrombocytopenia showed a strong association with postoperative stroke (Table 2). 
Multivariable analysis that incorporated postoperative platelet count as a time-varying 
continuous variable showed that, on a given postoperative day for every 30 x 10
9
/L
decrease in platelet counts, the risk for postoperative stroke increased by 12% 
(adjusted HR, 1.12; 95% CI, 1.01-1.24; P = 0.0255).
Early and delayed stroke
To study the impact of nadir platelet counts on timing of stroke after CABG 
surgery, patients were divided into 2 groups: early stroke (POD 0-1; n = 35) and delayed 
stroke (POD 2-30; n = 75). We then performed a stepwise multivariable competing risks 
proportional hazards model analysis following the Fine-Gray method to test for an 
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association between severity of postoperative thrombocytopenia defined as a time-
varying effect and timing of stroke. The results indicated that when postoperative 
platelet counts are defined as a time-varying covariate, moderate to severe 
thrombocytopenia was significantly associated with delayed, but not early postoperative 
stroke (Table 3). Similarly, when postoperative platelet counts were defined as a time-
varying continuous predictor, for every 30 x 10
9
/L decrease in platelet counts the risk for 
delayed postoperative stroke was significantly elevated (subdistribution adjusted HR, 
1.18; 95% CI, 1.04-1.35; P = 0.0109).
Sensitivity Analysis
Of the 6,130 subjects studied, 0.38% (n = 23) developed and received treatment 
for postoperative HIT. To determine whether the association between postoperative 
thrombocytopenia and postoperative stroke persisted, we repeated the analysis 
excluding patients with HIT. Both associations between daily moderate to severe 
postoperative thrombocytopenia (adjusted HR, 2.02; 95% CI, 1.20-3.39; P = 0.01) and 
daily platelet counts as a continuous variable (adjusted HR for every 30 x 10
9
/L 
decrease in platelet counts, 1.13; 95% CI, 1.02-1.25; P = 0.02) remained statistically 
significant. The association of delayed stroke with time-varying moderate to severe 
postoperative thrombocytopenia (adjusted subdistribution HR 2.93; 95% CI 1.52-5.68; P 
= 0.001) and time-varying postoperative platelet counts as a continuous variable 
(adjusted subdistribution HR 1.19; 95% CI 1.05-1.36; P = 0.009) also remained 
statistically significant.
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DISCUSSION
In this single-center study of 6,130 patients undergoing on-pump CABG surgery, we 
identified that moderate to severe postoperative thrombocytopenia was an independent 
risk factor for the development of postoperative stroke. Importantly, analysis of the
subdistribution hazards for early stroke (0-1 days post surgery) and delayed stroke (≥ 2 
days post surgery) demonstrated relation of thrombocytopenia with delayed but not with 
early stroke. Perioperative stroke signifies a dramatic setback for patients undergoing 
CABG surgery, not only for its neurological implications. Indeed, similar to previous 
reports,(1) patients who developed postoperative stroke in our study were at a 
significantly higher rate of 30-day mortality compared to patients without postoperative 
stroke (16.4% versus 1.2%, P < 0.0001). These numbers bear striking witness on the 
importance to identify modifiable predictors influencing postoperative stroke after CABG 
surgery.
Currently, the main clinical focus regarding platelets in cardiac surgery is 
centered on bleeding complications secondary to both quantitative and qualitative 
platelet defects. However, complications associated with increased platelet 
thrombogenicity have gained additional attention.(20-23) Most prominently, Mangano et 
al(20) found that early initiation of aspirin therapy after CABG surgery is associated with 
a reduction in stroke, myocardial infarction, renal failure, bowel infarction, and overall 
mortality. Aspirin appears safe in terms of bleeding risk,(24) but its efficacy to improve 
outcomes as a single agent may be limited by its relatively weak antiplatelet effect, as 
well as acquired perioperative aspirin resistance.(22) In addition, the timing of aspirin 
initiation immediately after CABG surgery varies considerably within the same institution 
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and among institutions, which may explain inconsistent results with aspirin use as a 
single preventive therapy.(24) Platelet inhibition with clopidogrel has also been shown to 
reduce ischemic complications in patients undergoing CABG surgery, but concerns of 
higher risk for perioperative bleeding complications has led to the common practice of 
preoperative discontinuation of clopidogrel therapy.(25) Hence, the best strategy for 
perioperative antiplatelet therapy remains uncertain. Antiplatelet medications such as 
the novel P2Y12 and protease-activated receptor 1 (PAR1) inhibitors, may offer a better 
bleeding risk profile while protecting against postoperative cardiovascular complications 
including stroke.(26,27) For instance, addition of ticagrelor, a novel P2Y12 inhibitor, as 
compared to aspirin alone has recently been shown to reduce the risk for graft occlusion
following CABG surgery.(27) A recent observational study demonstrated that vorapaxar, 
a novel PAR1 inhibitor, was associated with a reduced risk for composite outcomes of 
death, myocardial infarction, stroke, rehospitalization due to recurrent ischemia, and 
urgent revascularization, as compared to placebo after CABG surgery.(26) Neither 
ticagrelor or vorapaxar administration were associated with an increased risk for major 
bleeding complications.
Thrombocytopenia and platelet activation
We have recently demonstrated that low postoperative platelet counts are associated 
with an increased risk for AKI and death after CABG surgery,(13) which is similar to 
observations in critically ill patients(28) and in patients after transaortic valve 
replacement.(29) The mechanism for developing thrombocytopenia in these patients 
remains unclear, but the association of postoperative platelet counts with stroke after 
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CABG surgery suggests that the reduction in platelet numbers likely occurs in a context 
of increased platelet reactivity. This notion is supported by the fact that in a non-cardiac 
surgical context, low platelet counts are predictive of deep vein thrombosis,(30,31) and 
that a drop in platelet numbers is a risk factor for recurrence of pulmonary 
embolism,(32) re-infarction after ST-elevation MI,(33) and severity of stroke.(34) In 
addition, a study in patients with acute coronary syndrome demonstrated that low
platelet counts are associated with an increased risk for recurrent infarction, stroke, and 
death in drug-associated (ie, heparin, glycoprotein inhibitors) as well as drug-
independent thrombocytopenia.(35)
Early and delayed stroke
We observed nadir platelet counts on POD 2, which coincides with the increased 
spontaneous and stimulant-evoked platelet reactivity reported for the first week after 
CABG surgery.(36) Interestingly, our data on day-to-day variations of postoperative 
platelet counts also tightly correlated with the timing of stroke in our study, and in the 
study by Tarakji et al who found that stroke risk peaked approximately 40 hours after 
CABG surgery, stayed significantly elevated until day 5 after surgery, and then on POD 
6, stabilized at the steady background state reflective of the general risk factors in this 
population.(37) Indeed, a number of studies support our finding that most of the 
postoperative strokes were delayed (68%; n = 75).(4,37,38) The definition of early vs 
delayed stroke varies slightly in the above studies, yet this distinction may highlight 
important differences in postoperative stroke mechanisms. Several reports suggest that 
cardioembolic events (39) and ischemic events resulting from intraoperative 
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hypotension, cause most early strokes.(40) In contrast, underpinnings of delayed 
strokes may be significantly influenced by activation of systemic inflammation and 
hypercoagulability.(37) Of note, off-pump CABG is associated with a small reduction in 
stroke events compared to on-pump CABG; however, this difference was notable for 
early stroke only, which is consistent with reduced manipulation of the aorta.(41)
Interestingly, as part of our ongoing study, we recently reported a similar pattern of 
perioperative nadir platelet counts in on-pump versus off-pump CABG raising the 
question about the role of platelets in postoperative stroke in off-pump CABG 
surgery.(42)
Our finding that moderate to severe thrombocytopenia was associated with 
delayed but not early stroke, is intriguing, and supports the hypothesis that a 
postoperative prothrombotic state with associated platelet activation is an important 
factor in delayed stroke. Defining the mechanisms that drive these events will be crucial 
to the development of improved strategies to prevent postoperative stroke.
Risk factors for stroke
We confirmed the value of many previously described risk factors for predicting 
postoperative stroke and timing of stroke after CABG surgery.(1,4,43,44) In particular, 
advanced age, peripheral vascular disease, absence of preoperative statin use, 
intraoperative insertion of IABP, and administration of packed red blood cell 
transfusions were consistently significant predictors of postoperative stroke in our risk-
adjusted analysis. Further, when we studied the predictors of timing of postoperative 
stroke, we found that prior cerebrovascular accident was a predictor of early 
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postoperative stroke, whereas advanced age and intraoperative insertion of IABP were 
associated with delayed postoperative stroke. Importantly, we found that most of these 
risk factors were also associated with postoperative thrombocytopenia.
Advanced age, prior cerebrovascular accident, and peripheral vascular disease 
have previously been found to increase the risk for postoperative stroke. Patients with 
these risk factors often have widespread systemic vascular and cerebrovascular 
disease resulting in impaired cerebral blood flow and increased susceptibility to 
atheroembolism and thromboembolism in the perioperative period.(1,4,43) Because 
platelets play a central role in the pathophysiology of most vascular diseases and their 
associated ischemic complications, perioperative management of high-risk patients 
should include an evaluation of the benefits of dual antiplatelet therapy(27,45) or novel 
monotherapy, the latter of which may offer a better bleeding risk profile in the post 
CABG surgery setting.(26)
Our finding that statin use was associated with a lower risk for postoperative 
stroke, highlights the importance of adhering to current guidelines on initiation and 
maintenance of statin use for primary and secondary prevention of cardiovascular 
events in patients with ischemic heart disease.(45) In addition to their well known 
favorable effect on lipid profile, statins affect platelet activation and aggregation, 
endothelial cell function, and proliferation and migration of vascular smooth muscle 
cells.(45,46) All of these so-called pleiotropic properties of statins may substantially 
attenuate postoperative platelet activation and aggregation, and stabilize unstable 
atherosclerotic plaques, thereby reducing the risk for postoperative cardiovascular 
complications including stroke.
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The use of IABP has been linked to platelet activation and increased 
microthrombi generation due to mechanical stress during the IABP cycle and prolonged
exposure of blood components to the synthetic surface of the polyurethane balloon.(47)
Thus, our finding that the use of IABP is associated with both low platelet counts and an 
increased risk for postoperative stroke, calls into question the appropriateness of using 
heparin alone for anticoagulation in these patients, and suggests the need for a 
personalized and more comprehensive anticoagulation strategy, such as using heparin 
in combination of a GP IIb/IIIa inhibitor, or a GP IIb/IIIa inhibitor alone.(48)
Furthermore, our results support previous findings that link transfusion of packed 
red blood cells to increased risk for postoperative stroke in cardiac surgery.(44,49) As in 
these studies, our data cannot provide evidence of the causative effect of blood 
transfusion and thus the increased risk for stroke may stem from the effects of 
preceding anemia as well as from specific abnormalities introduced by the transfusion 
itself.(50) It is noteworthy, that transfused blood may trigger prothrombotic and 
inflammatory responses but also may have limited oxygen-carrying capabilities, 
especially if stored over longer periods.(51) However, irrespective of such 
considerations, evidence such as ours further highlights the importance of ongoing 
efforts to avoid excessive hemodilution and to establish clear blood transfusion 
guidelines for patients undergoing CABG surgery.
Limitations
Our study has several limitations due to its retrospective design. Information on 
clinical risk factors for postoperative stroke was not prospectively collected. Instead, 
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potentially relevant risk factors, medication use, and laboratory values, were retrieved 
from electronic health records, electronic intraoperative charts, physician 
documentation, and neuroimaging reports. Therefore, effects and the magnitude of 
effects of certain risk factors, medication use, and laboratory data may have been 
biased. However, the magnitude of their predictive values was similar to published 
findings from other studies.(4,43)
All patients were screened routinely during the postoperative period for evidence 
of postoperative stroke. While detailed preoperative baseline neurologic and 
neurocognitive assessments of these patients were not performed, the diagnosis of 
postoperative stroke was substantiated by neuroimaging, such as a CT or MRI head 
scan, in 91% of affected patients.
It has been suggested that intraoperative epiaortic ultrasound may reduce
cerebral emboli during CABG surgery by reducing aortic manipulation in atheroma rich 
sites.(52) However, such intervention would predominantly affected early postoperative 
stroke occurrence and not the more common delayed stroke as observed in several 
other reports including ours.(4,53)
This study was performed at a single tertiary center and therefore, our findings 
may not be fully applicable to other institutions with different perioperative practices and 
levels of experience. However, our reported incidences of postoperative stroke and risk 
factors were similar to other studies.(1,4)
In our study, we did not have a specific recorded time on perioperative blood 
product administration, and thus, we could not accommodate perioperative blood 
product administration in our extended Cox regression analysis as a time-dependent 
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variable to model its potential effect on postoperative stroke. Consequently, its effect on 
postoperative stroke may have been biased. Nevertheless, perioperative blood product 
administration in CABG surgery most frequently occurs intraoperatively through day 2 
after surgery; hence, the potential for observing a bias estimate of perioperative blood 
product administration on postoperative stroke is likely minimal.
Finally, no protocols were used to guide perioperative management of 
transfusion and anticoagulation therapies. Routine postoperative testing for HIT was left 
to the discretion of the intensive care unit team. Antiplatelet factor 4 antibodies are 
common after cardiac surgery with CPB, but only 3% of these patients develop HIT 
based on thrombotic sequel or serotonin-release assay.(54) As indicated by previous 
studies,(13,55) early-onset and persisting thrombocytopenia in cardiac surgery patients 
is seldom caused by HIT. Nevertheless, our sensitivity analysis indicated that after 
excluding patients with HIT, the association between postoperative thrombocytopenia 
and stroke persisted.
In summary, our findings suggest an independent association between moderate 
to severe postoperative thrombocytopenia and the development of postoperative stroke, 
and timing of stroke after CABG surgery. Our findings highlight the need for further 
studies to define mechanisms of perioperative platelet activation and its influence on 
adverse outcomes.
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Table 1. Demographic and clinical characteristics of the study population, N = 6,130
Characteristics Normal Platelet 
Count, 
>150x10
9
/L
(n = 1,750)
Mild 
Thrombocytopenia, 
100-150x10
9
/L
(n = 2,726)
Moderate/Severe 
Thrombocytopenia, 
<100x10
9
/L
(n = 1,654)
P value
Demographics
Age categories, years
<55
55-64
65-74
75-84
>84
Race
White
African American
Other
Female sex
517 (29.5)
593 (33.9)
465 (26.6)
165 (9.4)
10 (0.6)
1280 (73.1)
364 (20.8)
106 (6.1)
496 (28.3)
496 (18.2)
862 (31.6)
922 (33.8)
410 (15.0)
36 (1.3)
2111 (77.4)
469 (17.2)
146 (5.4)
670 (24.6)
212 (12.8)
464 (28.1)
578 (35.0)
360 (21.8)
40 (2.4)
1258 (76.0)
298 (18.0)
98 (5.9)
527 (31.9)
< 0.0001
0.0223
< 0.0001
Medical history*
EuroSCORE-related variables
Chronic obstructive 
pulmonary disease
Peripheral vascular disease
Cerebrovascular accident
Previous cardiac surgery
Serum creatinine > 2 mg/dL
Critical preoperative state
Unstable angina pectoris
Left ventricular function
Normal
Moderate dysfunction
Severe dysfunction
Recent myocardial 
infarction
Pulmonary hypertension
Diabetes mellitus
268 (15.3)
268 (15.3)
151 (8.6)
14 (0.8)
80 (4.6)
23 (1.3)
311 (17.8)
915 (52.3)
693 (39.6)
142 (8.1)
588 (33.6)
52 (3.0)
737 (42.1)
424 (15.6)
482 (17.7)
261 (9.6)
40 (1.5)
163 (6.0)
36 (1.3)
487 (17.9)
1,375 (50.4)
1,099 (40.3)
252 (9.2)
713 (26.2)
82 (3.0)
983 (36.1)
254 (15.4)
319 (19.3)
177 (10.7)
38 (2.3)
126 (7.6)
39 (2.4)
288 (17.4)
711 (43.0)
675 (40.8)
268 (16.2)
464 (28.1)
59 (3.6)
633 (38.3)
0.9720
0.0086
0.1217
0.0016
0.0009
0.0158
0.978
< 0.0001
< 0.0001
0.5203
0.0003
Laboratory tests results
Preoperative:
Platelet count, 10
9
/L
Creatinine, mg/dL
Hemoglobin, g/dL
266.0 [230.0, 315.0]
1.0 [0.9, 1.2]
12.9 [11.6, 14.2]
208.0 [179.0, 243.0]
1.1 [0.9, 1.3]
13.3 [11.9, 14.5]
176 [147.0, 212.0]
1.1 [0.9, 1.4]
13.0 [11.6, 14.3]
< 0.0001
< 0.0001
< 0.0001
Postoperative
†
Nadir platelet count, 10
9
/L
Maximum creatinine, mg/dL
†
Nadir hemoglobin, g/dL
177.0 [161.0, 201.0]
1.2 [1.0, 1.5]
8.9 [8.1, 9.7]
123.0 [111.0, 135.0]
1.2 [1.0, 1.6]
8.8 [8.1, 9.6]
82.0 [69.0, 92.0]
1.4 [1.1, 1.9]
8.7 [8.0, 9.4]
< 0.0001
< 0.0001
< 0.0001
Preoperative medications**
Acetylsalicylic acid
Alpha-receptor blockers
Angiotensin converting enzyme 
inhibitors
Angiotensin II receptor 
antagonist
Beta-receptor blockers
Calcium-channel blockers
Clopidogrel
Diuretics
Nitrates
Statins
Warfarin
1124 (64.9)
75 (4.3)
680 (39.0)
153 (8.8)
1027 (59.3)
341 (19.7)
228 (13.2)
473 (27.3)
678 (39.2)
961 (55.5)
32 (1.9)
1768 (64.9)
142 (5.2)
1036 (38.6)
230 (8.5)
1590 (58.9)
499 (18.5)
332 (12.3)
663 (24.6)
997 (36.9)
1463 (54.2)
79 (2.9)
1067 (64.5)
96 (5.8)
616 (37.7)
138 (8.4)
971 (59.1)
293 (17.9)
199 (12.2)
486 (29.7)
609 (37.3)
873 (53.4)
71 (4.3)
0.9382
0.1246
0.6275
0.9038
0.9274
0.3905
0.6123
0.0008
0.2955
0.4518
0.0001
Intraoperative characteristics
Year of surgery
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
Duration of cardiopulmonary 
bypass, minutes
Duration of aortic cross clamp, 
minutes
Intraoperative insertion of intra-
aortic balloon pump
155 (8.9)
159 (9.1)
130 (7.4)
135 (7.7)
119 (6.8)
115 (6.6)
113 (6.4)
99 (5.7)
113 (6.5)
123 (7.0)
86 (4.9)
85 (4.8)
96 (5.5)
133 (7.6)
89 (5.1)
111.0 [91.0, 136.0]
64.0 [49.0, 83.0]
88 (5.0)
349 (12.8)
313 (11.5)
251 (9.2)
178 (6.5)
166 (6.1)
158 (5.8)
162 (5.9)
156 (5.7)
177 (6.5)
148 (5.4)
136 (5.0)
141 (5.2)
142 (5.2
155 (5.7)
94 (3.5)
121.0 [98.0148.0]
70.0 [52.0, 88.0]
180 (6.6)
240 (15.0)
210 (12.7)
141 (8.5)
99 (6.0)
116 (7.0)
118 (7.1)
88 (5.3)
91 (5.5)
91 (5.5)
93 (5.6)
73 (4.4)
63 (3.8)
82 (5.0)
84 (5.1)
57 (3.5)
133.0 [106.0, 167.0]
75.0 [56.0, 95.0]
248 (15.0)
< 0.0001
< 0.0001
< 0.0001
< 0.0001
Intraoperative medications
Aminocaproic acid
Aprotinin
Epinephrine
Norepinephrine
Vasopressin
Nitroprusside
Nitroglycerin
Esmolol
Metoprolol
Tranexamic acid
1256 (71.8)
182 (10.4)
532 (30.4)
68 (3.9)
459 (26.2)
484 (27.7)
890 (50.9)
43 (2.5)
1067 (61.0)
251 (14.3)
1,959 (71.9)
322 (11.8)
907 (33.3)
139 (5.1)
720 (26.4)
788 (28.9)
1,546 (56.7)
63 (2.3)
1,698 (62.3)
294 (10.8)
1,143 (69.1)
250 (15.1)
750 (45.3)
152 (9.2)
458 (27.7)
490 (29.6)
935 (56.5)
47 (2.8)
949 (57.4)
176 (10.6)
0.1131
0.0001
< 0.0001
< 0.0001
0.5647
0.4335
0.0002
0.5473
0.0051
0.0004
Perioperative blood product 
use within 2 days
Red blood cells, mL
Fresh frozen plasma, mL
Platelets, mL
Cryoprecipitate, mL
778 (44.5)
193 (11.0)
289 (16.5)
27 (1.5)
1,567 (57.5)
573 (21.0)
755 (27.7)
100 (3.7)
1,240 (75.0)
576 (34.8)
751 (45.4)
127 (7.7)
< 0.0001
< 0.0001
< 0.0001
< 0.0001
Values are expressed as mean + standard deviation, median [interquartile range], or n (%).
*The definitions of these risk factors were based on the definitions used by the European System for Cardiac 
Operative Risk Evaluation (EuroSCORE) scoring system.
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†
Postoperative nadir platelet counts and hemoglobin concentrations were defined as the lowest in-hospital values. 
In patients who experienced postoperative stroke, the lowest platelet value and hemoglobin value prior to stroke 
were used.
**
Due to missing data (1.03%), preoperative medication use was computed for n = 1,731 patients with normal 
platelets, for n = 2,701 patient with mild thrombocytopenia, and for n = 1,635 patients with moderate/severe 
thrombocytopenia.
Table 2. Univariable and multivariable predictors of postoperative stroke
Predictors Univariable Multivariable*
Hazard Ratio 
(95% Confidence 
Interval)
P value Hazard Ratio 
(95% Confidence 
Interval)
P value
Demographics
Age at surgery, per 5-year increase
Race
White
African American
Other
Female sex
Clinical risk factors
Chronic obstructive pulmonary disease
Peripheral vascular disease
Cerebrovascular accident
Previous cardiac surgery
Preoperative serum creatinine > 2 mg/dL
Critical preoperative state
Unstable angina pectoris
Left ventricular function
Normal
Moderate dysfunction
Severe dysfunction
Recent myocardial infarction
Pulmonary hypertension
Diabetes mellitus
Laboratory tests
Preoperative:
Platelet count, per 30 x 10
9
/L decrease
Hemoglobin, per 1 g/dL decrease
Postoperative:
Daily hemoglobin, per 1 g/dL decrease
Daily platelet count
Normal, >150x10
9
/L
Mild thrombocytopenia, 100-150x10
9
/L
Moderate/severe thrombocytopenia, 
<100x10
9
/L
Preoperative medications
1.24 (1.13 – 1.36)
1.0
1.00 (0.62 – 1.62)
0.46 (0.15 – 1.46)
1.63 (1.11 – 2.39)
1.37 (0.86 – 2.19)
1.79 (1.17 – 2.72)
1.98 (1.21 – 3.24)
1.22 (0.30 – 4.95)
0.90 (0.40 – 2.05)
2.95 (1.20 – 7.24)
1.10 (0.68 – 1.76)
1.0
1.58 (1.05 – 2.37)
1.78 (1.00 – 3.16)
0.76 (0.49 – 1.19)
0.57 (0.14 – 2.30)
0.88 (0.60 – 1.30)
1.08 (0.98 – 1.16)
1.02 (0.93 – 1.12)
1.03 (0.89 – 1.19)
1.0
1.64 (1.02 – 2.62)
2.77 (1.66 – 4.61)
< 0.0001
0.9846
0.1893
0.0132
0.1828
0.0067
0.0069
0.7786
0.8068
0.0180
0.7030
0.0283
0.0513
0.2312
0.4267
0.5244
0.1124
0.6699
0.6826
0.0406
< 0.0001
1.18 (1.08 – 1.30)
1.66 (1.09 – 2.52)
1.0
1.40 (0.87 – 2.24)
1.99 (1.18 – 3.34)
0.0006
0.0193
0.1661
0.0093
Acetylsalicylic acid
Alpha-receptor blockers
Angiotensin converting enzyme inhibitors
Angiotensin II receptor antagonist
Beta-receptor blockers
Clopidogrel
Diuretics
Nitrates
Statins
Warfarin
Intraoperative characteristics
Year of surgery, per year increase
Duration of cardiopulmonary bypass, per 30-
minute increase
Duration of aortic cross clamp, per 30-minute
increase
Intraoperative insertion of intra-aortic balloon 
pump
Intraoperative medications
Aminocaproic acid
Aprotinin
Epinephrine
Norepinephrine
Vasopressin
Esmolol
Metoprolol
Tranexamic acid
Perioperative blood product use within 2 days
Red blood cells
Fresh Frozen Plasma
Platelets
Cryoprecipitate
1.10 (0.74 – 1.63)
0.34 (0.08 – 1.37)
0.81 (0.55 – 1.20)
0.95 (0.48 – 1.87)
0.96 (0.66 – 1.40)
1.19 (0.70 – 2.02)
0.85 (0.55 – 1.32)
0.95 (0.64 – 1.40)
0.67 (0.46 – 0.98)
0.59 (0.15 – 2.41)
0.97 (0.92 – 1.01)
1.10 (0.99 – 1.23)
1.03 (0.86 – 1.23)
2.14 (1.29 – 3.55)
0.91 (0.60 – 1.36)
2.00 (1.27 – 3.15)
1.40 (0.96 – 2.04)
1.61 (0.84 – 3.09)
0.98 (0.64 – 1.50)
0.72 (0.18 – 2.92)
0.97 (0.67 – 1.43)
0.51 (0.24 – 1.09)
2.20 (1.42 – 3.39)
1.60 (1.07 – 2.40)
1.81 (1.24 – 2.64)
1.11 (0.45 – 2.72)
0.6547
0.1286
0.2986
0.8779
0.8363
0.5167
0.4634
0.7806
0.0384
0.4658
0.1096
0.0880
0.7388
0.0031
0.6342
0.0026
0.0794
0.1488
0.9406
0.6482
0.8952
0.0835
0.0004
0.0220
0.0220
0.8226
0.69 (0.47 – 1.00)
2.10 (1.26 – 3.51)
1.62 (1.04 – 2.54)
0.0492
0.0043
0.0338
*The final multivariable Cox regression analysis was based on n = 6,067 due to missing information (n = 63) on preoperative 
medication use. Predictors of preoperative calcium-channel blocker use, and intraoperative nitroprusside and nitroglycerine use failed 
the proportional hazards assumption and could not be assessed via Cox regression analysis. The test of difference in survival function 
was performed via Wilcoxon test of the Kaplan-Meier estimate between strata, and indicated that the probability of remaining stroke 
free in patients with preoperative calcium-channel blocker use (P = 0.1918), and intraoperative nitroprusside (P = 0.1071) and 
nitroglycerine (P = 0.2739) use were not statistically not different compared to patients who did not receive these medications.
The variables with P < 0.05 in the final multivariable model were selected by means of a forward stepwise technique.
Table 3. Multivariable predictors of timing of stroke
Predictors Model for Early Stroke Model for Delayed Stroke
Subdistribution Hazard 
Ratio
(95% Confidence Interval)
P value Subdistribution Hazard 
Ratio
(95% Confidence Interval)
P value
Age at surgery, per 5-year increase
Female sex
Previous cerebrovascular accident
Intraoperative nitroprusside administration
Intraortic balloon pump insertion
Postoperative daily platelet count
Normal, >150x10
9
/L
Mild thrombocytopenia, 100-150x10
9
/L
Moderate/severe thrombocytopenia, <100x10
9
/L
2.74 (1.25 – 6.04)
2.94 (1.51 – 5.71)
1.0
1.17 (0.55-2.48)
1.23 (0.51-2.99)
0.0122
0.0015
0.6765
0.6497
1.22 (1.08 – 1.37)
1.74 (1.09 – 2.76)
2.90 (1.65 – 5.11)
1.0
1.75 (0.95 – 3.22)
2.87 (1.49 – 5.55)
0.0009
0.0192
0.0002
0.0736
0.0002
*The final multivariable Cox regression analysis was based on n = 6,067 due to missing information (n = 63) on preoperative medication use.
While in the primary stroke outcome model intraoperative nitroprusside use failed the proportional hazards assumption, for the early stroke 
subevent analysis there was no evidence of a non-proportional hazard (test for time effect in model p=0.46), and thus, intraoperative 
nitroprusside use was included as predictor of this analysis.
Early strokes (n = 35), delayed strokes (n = 75).
